Loading
A report of one patient whose infused melanoma-targeting T cells also attacked normal pigment cells in the skin, which the authors called the first direct evidence in humans that such cells can harm healthy tissue carrying the same protein.
A patient with metastatic melanoma developed inflammatory lesions around pigmented areas of skin after an infusion of MART-1-specific CD8+ T-cell clones (Journal of Experimental Medicine 2000). Tetramer analysis showed MART-1-specific CD8+ T cells, identical to the infused clones by CDR3 sequencing, made up more than 28 per cent of CD8 T cells in the skin, and post-infusion biopsies showed loss of MART-1 expression and absence of melanocytes in affected skin (Journal of Experimental Medicine 2000).
Targeting a protein that tumours share with normal cells can damage those normal cells too; the authors state this was the first direct evidence of it in humans, which shaped later thinking on on-target, off-tumour toxicity.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/